Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292482 | 0.91 | TDP1 (0.62) | TDP1L3MBTL1MEN1NPC1RAB9A | |
| SCHEMBL2270688 | 0.87 | PYGM (0.58) | TDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL2295612 | 0.85 | CYP1A2 (0.64) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2290704 | 0.85 | SMN1; SMN2 (0.57) | TDP1L3MBTL1MEN1NPC1RAB9A | |
| SCHEMBL2291520 | 0.85 | SMN1; SMN2 (0.57) | TDP1L3MBTL1MEN1NPC1RAB9A | |
| SCHEMBL30466712 | 0.83 | MEN1 (0.72) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2025586 | 0.83 | MEN1 (0.72) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2292518 | 0.82 | SERPINE1 (0.71) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2288377 | 0.81 | SERPINE1 (0.60) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2292384 | 0.81 | MEN1 (0.63) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989657-B2 | Anthranilic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | claimed |
| US-20090247637-A1 | Novel Anthranilic Acid Derivatives | DEHMLOW HENRIETTA | 2009-10-01 | — | — | US | claimed |
| JP-2008546661-A | — | — | 2008-12-25 | — | — | JP | claimed |
| EP-1896396-A1 | ANTHRANILIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-03-12 | — | — | EP | claimed |
| WO-2006134040-A1 | ANTHRANILIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-21 | — | — | WO | claimed |
| US-20060281810-A1 | Novel anthranilic acid derivatives | HOFFMANN-LA ROCHE INC. | 2006-12-14 | — | — | US | claimed |
| US-7989657-B2 | Anthranilic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090247637-A1 | Novel Anthranilic Acid Derivatives | DEHMLOW HENRIETTA | 2009-10-01 | — | — | US | disclosed |
| EP-1896396-A1 | ANTHRANILIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006134040-A1 | ANTHRANILIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281810-A1 | Novel anthranilic acid derivatives | HOFFMANN-LA ROCHE INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281810-A1 | Novel anthranilic acid derivatives | GPR84, HCAR1, GPR88 | TDP1 4399/4885L3MBTL1 4768/4885MEN1 1329/4885 |
| US-20090247637-A1 | Novel Anthranilic Acid Derivatives | GPR84, GPR88, HCAR1 | TDP1 4638/4885L3MBTL1 4763/4885MEN1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.